

References

- **Abraham S, Begum S, Isenberg D.** Hepatic manifestations of autoimmune rheumatic diseases. *Ann Rheum Dis* 2004; 63:123–129.
- **Agnella V, DeRosa F:** Extrahepatic disease manifestations of HCV Infection: some current issues. *J Hepatol* 2004, 40:341–352.
- **Ala A, Schilsky ML. (2004)** Wilson's disease: pathophysiology, diagnosis, treatment ,and screening. *Clin Liv Dis* 2004;8(4):787–805.
- **Alvarez F, Berg Pa, Bianchi Fb et al. (1999)** International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. *J. Hepatology* 31:929-938.
- **American Thoracic Society/European Respiratory Society:** Standards for the Diagnosis and Management of Individuals

with Alpha-1 Antitrypsin Deficiency Lung Disease. *Am J Respir Crit Care Med* 2003;168:823–49.

- **Anonymous.** Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Post exposure Prophylaxis. *MMWR Recomm Rep* **2004**;50(RR-11):1.
- **American Gastroenterological Association.** American Gastroenterological Association Medical Position Statement: Osteoporosis in Hepatic Disorders *Gastroenterology* 2003;125:937–940.
- **American Gastroenterological Association.** AGA Technical Review on Osteoporosis in Hepatic Disorders. *Gastroenterology* 2003;125:941–966.
- **Armstrong GL, Alter MJ,McQuillan GM,Margolis HS.** The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. *Hepatology* 2000 Mar;31(3):777–82.

-
-
- **Bachmann, M.F., Hunziker, L., Zinkernagel, R.M., Storni, T., Kopf, M. (2004).** Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key. *European Journal of Immunology*, 34: 317–326.
 - **Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN.** The incidence of fracture among patients with inflammatory bowel disease- a population-based cohort study. *Ann Intern Med* 2000;133:795–799.
 - **Berenguer M, Ferrell L, Watson J et al.** HCV related fibrosis progression following liver transplantation: increase in recent years. *J. Hepatol.* 2000; 32: 673.
 - **Bertolino P, McCaughan GW , Bowen DJ.** Immunological Parameters Influencing Adaptive Immune Responses to the Hepatitis C Virus : *Hepatitis C Virus Disease*, 2008; chapter 3 : 39-71.
 - **Biagini MR, Tozzi A, Milani S, et al.** Fatigue in primary biliary cirrhosis: a possible role of comorbidities. *European Journal of Gastroenterology & Hepatology* 2008, 20:122–126.

- **Blackard JT, Kemmer N, and Sherman KE.** Extrahepatic Replication of HCV: Insights Into Clinical Manifestations and Biological Consequences : *Hepatology* 2006;44:15-22.
- **Block TM, Guo H ,and Guo JT.** Molecular Virology of Hepatitis B Virus for Clinicians : *Clin Liver Dis* 11 (2007) 685–706.
- **Bonkovsky HL, Mehta S:** Hepatitis C: A review and update. *J Am Acad Dermatol* 2001, 44:159–182.
- **Bowman AR, Dass DA, Dissanayake IR.** The role of testosterone in cyclosporin- induced osteopenia. *J Bone Miner Res* 1997;12:607-615.
- **Buskila D.** Hepatitis C-associated rheumatic disorders; *Rheum Dis Clin North Am* 2009; 35:111-123.
- **Cacoub P, Ratziu V, Myers RP, et al.:** Impact of treatment on extrahepatic manifestations in patients with chronic hepatitis C. *J Hepatol* 2002, 30:812–818.

-
-
- **Cacoub, P., Renou, C., Kerr, G., Hue, S., Rosenthal, E., Cohen, P., Kaplanski, G., Charlotte, F., Thibault, V., Ghillani, P., Piette, J.C., and Caillat-Zucman, S. (2001).** Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. *Arthritis Rheum.* **44**:2118–2124.
 - **Campos MA, Wanner A, Zhang G, Sandhaus RA.** Trends in the diagnosis of symptomatic patients with alpha-1 antitrypsin deficiency between 1968 and **2003**. *Chest* 2005;128:1179–86.
 - **Carrell, R, Lomas, D.** Alpha-1 antitrypsin deficiency- a model for conformational diseases. *N Engl J Med* **2002**;346:45–53.
 - **Casals MR and Font J :** Extrahepatic manifestations in patients with chronic hepatitis C virus infection *Current Opinion in Rheumatology* 2005, 17:447—455.

-
- **Cauch-Dudek K, Abbey S, Stewart DE, and Heathcote EJ.** Fatigue in primary biliary cirrhosis. *Gut*, **1998**;43:705–710.
 - **Centers for Disease Control and Prevention.** General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). *MMWR Morb Mortal Wkly Rep* 2002;51:1–36.
 - **Chalasani N, Fontana R, Watkins PB, et al.** Drug Induced Liver Injury Network (DILIN) prospective study: initial results (abstracted). *Am J Gastroenterol* **2006**;101 (9 Suppl):S169.
 - **Chan, C.W., Crafton, E., Fan, H.N., Flook, J., Yoshimura, K., Skarica, M., Brockstedt, D., Dubensky, T.W., Stins, M.F., Lanier, L.L., Pardoll, D.M., Housseau, F. (2006).** Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. *Nature Medicine*, 12: 207–213.
 - **Chen CJ, Iloeje UH, Yang HI.** Long-Term Outcomes in Hepatitis B: The reveal-HBV Study : *Clin Liver Dis* 11 (2007) 797–816
-

- **Christie JM and Chapman RW** . Non-viral liver disease :Drug Therapy for Gastrointestinal and Liver Diseases **2001**: chapter 12 ; 259- 273 .
- **Crawford BA, Labio ED, Strasser SI, McCaughan GW.** Vitamin D replacement for cirrhosis-related bone disease. Nature clinical practice, gastroenterology and hepatology 2006;3(12):689-699.
- **Czaja AJ.** Current concepts in autoimmune hepatitis. Ann Hepatol 2005;4:6–24. Important review of the diagnostic criteria, pathogenic mechanisms, and treatment strategies of autoimmune hepatitis.
- **Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, et al.** Long-term prognosis of fatty liver: Risk of chronic liver disease and death. Gut 2004;53:750–5.
- **De Valle MB, Klinteberg VA, Alem N, et al.** Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther 2006; 1187– 95.

- **Donaldson Pt (1999)** :TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal [editorial; comment]. *J Hepatol* 31:366-368.
- **Duffy J. Arthritis and hepatitis.** *Bull Rheum Dis.* 1998;47:1–5.
- **Dunn C, Brunetto M, Reynolds G, et al.** Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. *J Exp Med* 2007;204(3):667–80.
- **Fanning L, Kenny-Walsh E, Levis J et al.** Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. *Hepatology* 2000; 31: 225.
- **Fattovich G, PantalenaM, Zagni I, et al.** Effect of hepatitis B and C virus infections on thenatural history of compensated cirrhosis: a cohort study of 297 patients.*AmJ Gastroenterol* 2002;97:2886–95.

-
-
- **Featherstone B.** Causes of liver disease and dysfunction: Drugs and the Liver, **2008** : chapter 3 :54-72 .
 - **Ferri C, Antonelli A, Mascia M.T, et al.** B cells and mixed cryoglobulinemia. *Autoimmun Rev* 2007; 7: 114-20.
 - **Ferri C, Sebastiani M, Guigliolo D, Cazzato M, Longombardo G, Antonelli A, Puccini R, Michelassi C, Zignego AL.** Mixed cryoglobulinaemia: demographic, clinical, and serologic features and survival in 231 patients. *Semin Arthritis Rheum* 2004; 33: 355- 374.
 - **Ferri C, Zignego AL, Pileri SA.** Cryoglobulins. *J Clin Pathol* 2002; 55: 4-13.
 - **Fleming JW, Mullen KD.** Practical Management of Liver Diseases: Wilson's Disease 2008 ; chapter 8 :131-140.
 - **Fusconi M, Vannini A., Dallaglio A.C ,etal.** Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis *Aliment Pharmacol Ther* 2005; 22: 951–955.

-
- **Galhenage S, McHutchison JG:** Practical Management of Liver Diseases 2008; Chronic Hepatitis C CHAPTER 3: 39-55.
 - **Gebo KA, Herlong HF, Torbenson MS, et al.** Role of liver biopsy in management of chronic hepatitis C: a systematic review. *Hepatology* **2002**;36(5 Suppl 1):S161.
 - **Gitto S, Micco L, Conti F, Andreone P, Bernardi M.** Alcohol and viral hepatitis: A mini-review. *Dig Liver Dis* **2008**.
 - **Girelli D, Bozzini C, Roetto A.** Clinical and pathological finding in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. *Gastroenterology* 2002;122:1295-1302 .
 - **Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, et al.** The true impact of fatigue in primary biliary cirrhosis: a population study. *Gastroenterology* 2002; 122:1235–1241

- **Gossard AA and Lindor KD.** Autoimmune Liver Disease ; Practical Management of Liver Diseases **2008** chapter 10: 159-171.
- **Gow PJ, Smallwood RA, Angus PW et al.** Diagnosis of Wilson's disease: an experience over three decades. *Gut* 2000; 46: 415.
- **Graziadi IW, Joseph JJ, Wiesner RH et al.** Increased risk of chronic liver failure in adults with heterozygous α_1 -antitrypsin deficiency. *Hepatology* **1998; 28**: 1058.
- **Greenberg PL, Baer MR, Bennett JM, et al.** Myelodysplastic syndromes clinical practice guidelines in oncology. *J Natl Compr Canc Netw* **2006;4**:58-77.
- **Guichelaar MJ, Malinchoc M, Sibonga J, et al.** Bone Metabolism in Advanced Cholestatic Liver Disease: Analysis by Bone Histomorphometry. *Hepatology* 2002;36(4):895-903.

- **Guillevin L, Mahr A, Callard P, et al.** Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. *Medicine (Baltimore)* 2005; 84:313–322.
- **Hadziyannis SJ, Sette H, Jr, Morgan TR, et al.,** PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* **2004**;140:346.
- **Harrison BJ, Thomson W, Pepper L, Ollier WER Chakravarty K, Barrett EM et al.,** Patients who develop inflammatory polyarthritis (IP) after immunization are clinically indistinguishable from other patients with IP. *BrJ Rheumatol* 1997;36:366–9.
- **Hattori A, Wakusawa S, Hayashi H, et al.** AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. *Hepatol Res* **2003**;26:154-156.
- **Hay JE.** Bone Disease in Cholestatic Liver Disease. *Gastroenterology* 1995;108:276-283.

- **Heiland GR, Aigner E, Dallos T, et al.** Synovial immunopathology in haemochromatosis arthropathy *Ann Rheum Dis* 2010;69:1214–1219.
- **Herrera I, Concha R, Molina EG, et al.** Relapsing polychondritis, chronic hepatitis C virus infection, and mixed cryoglobulemia. *Semin Arthritis Rheum* 2004; 33:388—403.
- **Hoofnagle JH.** Course and Outcome of Hepatitis C; *Hepatology* 2002;36:S21-S29.
- **Hoofnagle JH, Doo E, Liang TJ, et al.** Management of hepatitis B: summary of a clinical research workshop. *Hepatology* 2007;45(4):1056–75.
- **Hraber P, Kuiken C, Yusim K.** Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. *Hepatology* 2007;46(6):1713.
- **Hui CK, Belaye T, Montegrande K, Wright TL.** A comparison in the progression of liver fibrosis in chronic

hepatitis C between persistently normal and elevated transaminase. *J Hepatol* 2003;38:511.

- **Initiative for Vaccine Research, Viral Cancers, Hepatitis C.** World health Organization, 2006. Accessed 1st November, 2006, at http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html.
- **International Autoimmune Hepatitis Group.** Report: review of criteria for diagnosis of autoimmune hepatitis. *J. Hepatol.* 1999; 31: 929.
- **Jamal MM, Soni A, Quinn PG et al.** Clinical features of hepatitis-C infected patients with persistently normal alanine transferase levels in the south-western United States. *Hepatology* 1999; 30: 1307.
- **Jonsson JR, Purdie DM, Clouston AD, Powell EE.** Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy. *Mol Diagn Ther* 2008;12(4):209.

-
-
- **Kessel A, Rosner I, Zuckerman E, Golan TD, Toubi E.** Use of antikeratin antibodies to distinguish between rheumatoid arthritis and polyarthritis associated with hepatitis C infection. *J Rheumatol* 2000;27:610–2.
 - **Kitzberger R, Madl C, Ferenci P.** Wilson disease. *Metab Brain Dis*, 2005;20(4):295–302.
 - **Klein J, Sato A.** The HLA system. First of two parts. *N Engl J Med* 2000;343(10):702–9.
 - **Krawitt EL :** Autoimmune hepatitis; *N Engl J Med*, 2006 Jan 5;354(1):54-66.
 - **Kremsdorf D, Soussan P, Paterlini-Brechot P, et al.** Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. *Oncogene* 2006;25(27): 3823–33.
 - **Lee WM.** Drug-induced hepatotoxicity. *N Engl J Med* 2003;349:474–85.
 - **Leuschner U.** Primary biliary cirrhosis—presentation and diagnosis. *Clin Liver Dis*, 2003;7:741–58.

- **Liang TJ.** Hepatitis B: The Virus and Disease : **HEPATOLOGY 2009;49:S13-S21.**
- **Lidove O, Cacoub P, Maisonneuve T, Servan J, Thibault V, Piette JC, et al.** Hepatitis C virus infection with peripheral neuropathy is not always associated with cryoglobulinaemia. *Ann Rheum Dis* 2001; 60: 290-2.
- **Lim YS, Kim WR.** The global impact of hepatic fibrosis and end-stage liver disease. *Clin Liver Dis* **2008;12(4):733.**
- **Lindor KD.** Cholestatic Liver Disease: Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and AIDS-Associated Cholangiopathy. *Mayo Clinic Gastroenterology and Hepatology Board Review* **2008:** chapter 29 : 377-383.
- **Loustaud-Ratti V, Riche A, Liozon E, Labrousse F, Soria P, Rogez S, et al.** Prevalence and characteristics of Sjogren's syndrome or Sicca syndrome in chronic hepatitis C virus infection: a prospective study. *J Rheumatol* 2001;28:2245–51.

-
- **Lupberger J, Hildt E.** Hepatitis B virus-induced oncogenesis. *World J Gastroenterol* 2007; 13(1):74–81 .
 - **Maillefert JF, Farge P, Gazet-Maillefert MP, Tavernier C,** Mental nerve neuropathy as a result of hepatitis B vaccination, *Oral Surg Oral Med Oral Pathol Radiol Endod* 1999;83:663-4.
 - **Mandavam S.** Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. *Semin Liver Dis* **2004**;24:217–32.
 - **Marcellin P.** Hepatitis C: the clinical spectrum of the disease. *J. Hepatol.* 1999; 31 (suppl. 1): 9.
 - **Marcos Y, Fainboim, Capucchio M ,etal.** Two-locus Involvement in the Association of Human Leukocyte Antigen with the Extrahepatic Manifestations of Autoimmune Chronic Active Hepatitis. *Hepatology* 1994;19:1371-1374.
 - **Mayo MJ:** Extrahepatic manifestations of hepatitis C infection, Southwest. *Int Med Conf* 2002, 325:135–148.

-
- **McMahon.** The natural history of chronic hepaatitis B virus infection. *HEPATOLOGY* **2009**;49(suppl):S45-S55.
 - **McNally PR.** Rheumatological manifestations in hepatobiliary diseases, *GI/Liver secrets plus* 2010; Chapter 23;167-172.
 - **Medzhitov R, Janeway C Jr.** Innate immunity. *N Engl J Med* 2000;343(5):338–44.
 - **Meier Y, Cavallaro M, Roos M, et al.** Incidence of drug-induced liver injury inmedical inpatients. *Eur J Clin Pharmacol* **2005**;61:135–43.
 - **Menon KVN, Angulo P, Weston S, Dickson ER, and Lindor KD.** Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. *J Hepatol*, **2001**;35:316–323.
 - **Milich D, Liang TJ.** Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. *HEPATOLOGY* **2003**;38:1075-1086.

- **Moseley RH.** Approach to the patient with abnormal liver chemistries principles of Clinical Gastroenterology 2008; chapter 21;399-417.
- **Nakchband IA, Van der Merwe SW.** Current understanding of osteoporosis associated with liver disease. Gastroenterol. Hepatol.2009;6:660-670.
- **Nathan SD, and Stoller JK.** Alpha-1 Antitrypsin Deficiency and the Liver; PracticalManagement of Liver Diseases 2008:chapter 9: 140-154.
- **Needham M, Stockley RA.** Alpha-1 antitrypsin deficiency 3: Clinical manifestations and natural history. Thorax 2004;59:441–5.
- **Nick H, Acklin P, Lattmann R, et al.** Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-1076.

-
- **Niederau C.** Iron overload and atherosclerosis. *Hepatology* 2002;32:569-674.
 - **Niederau C:** hepatology A clinical textbook, Chapter 24: Metabolic Liver Diseases: Haemochromatosis 2009 :395-419 .
 - **Njajou OT, Vaessen N, Joosse M, et al.** A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. *Nat Genet* 2001;28:213-214.
 - **Nyquist F, Ljunghall S, Berglund M, Obrant K.** Biochemical markers of bone metabolism after short and long time ethanol withdrawal in alcoholics. *Bone* 1996;19:51–54.
 - **O’Shea R, Dasarathy S and McCullough AJ.** Alcoholic Liver Disease : PracticalManagement of Liver Diseases chapter 6; **2008** :101-111.
 - **Oder W, Prayer L, Grimm G et al.** Wilson’s disease: evidenceof subgroups derived from clinical findings and brainlesions. *Neurology* **1993**; 43: 120.

- **Pawlotsky, J.M.** (2004). Pathophysiology of hepatitis C virus infection and related liver disease. *Trends in Microbiology*, 12: 96–102.
- **Pawlotsky ,Le Dantec P, Moirand R, etal.** Elevated parathyroid hormone and osteoarticular changes in patients with genetic hemochromatosis. *Arthritis and rheumatism* 1999;42(4):799-806.
- **Poethko-Muller C, Kuhnert R, Schlaud M.** [Vaccination coverage and predictors for vaccination level. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2007;50(5-6):851.
- **Polson j and Chalasani N.** Drug-Induced Liver Disease (DILI) ;Practical Management of Liver Diseases 2008 : chapter 11 : 174-195.
- **Porter JB** Practical management of iron overload. *Br J Haematol* 2001;115:239-252.

- **Poterucha JJ.** Mayo Clinic Gastroenterology and Hepatology Board Review 2008 ; CHAPTER 28 Metabolic Liver Disease; 363-376.
- **Poynard T** :Natural history of hepatitis B: Extra-hepatic manifestations and quality of life(chapter 3) : Hepatitis B and C Management and Treatment , 2002 : 17-21 .
- **Primhak RA, Tanner MS.** Alpha-1 antitrypsin deficiency. Arch Dis Child. 2001;85:2–5.
- **Puchner KP and Berg T:** Chapter 16: Extrahepatic manifestations of chronic HCV; Hepatology 2009, 255-274.
- **Qirbi N, Hall AJ.** Epidemiology of hepatitis B virus infection in the Middle East.East Mediterr Health J 2001 Nov; 7(6): 1034–1045.
- **Ramos-Casals M, Brito-Zeron P, Yague J, et al.** Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology (Oxford). 2005; 44:89—94.

- **Ramos-Casals M, Loustaud-Ratti V, De Vita S, et al.** Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases. *Medicine (Baltimore)* 2005; 84:81—89.
- **Rantala M, van de Laar MJ.** Surveillance and epidemiology of hepatitis B and C in Europe – a review. *Euro Surveill* 2008;13(21).
- **Raza K, Breese M, Nightingale P, et al.** Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. *J Rheumatol* 2005; 32: 231–8.
- **Rehermann B.** Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. *Semin Liver Dis* 2007;27(2):152–60.
- **Rezaei N.** Therapeutic targeting of pattern-recognition receptors. *Int Immunopharmacol* 2006;6(6):863–9.
- **Riviere, Vergniol J, Reffet A, et al.** Gastric variceal bleeding uncovering a rare association of CREST syndrome, primary biliary cirrhosis, nodular regenerative hyperplasia and

pulmonary hypertension. European Journal of Gastroenterology & Hepatology 2010;00:1-4.

- **Roberts, EA, Cox DW.** Zakim and Boyer's Hepatology. Wilson's Disease. Thomas D Boyer, Teresa L.Wright, Michael P Manns, eds. 5th ed., 1221. Saunders, **2006**.
- **Roberts EA, Schilsky ML.** A Practice Guideline on Wilson Disease. Hepatology **2003**;37:1475-92.
- **Roetto A, Totaro A, Cazzola M, et al.** Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999;64:1388-1393.
- **Rouillard S, Lane NE.** Hepatic Osteodystrophy Hepatology 2001;33(1):301-7.
- **Saab S, Rosen H.** Approach to the patient with chronic viral hepatitis B or C: principles of Clinical Gastroenterology, 520-525, 2008.

- **Saadoun D, Asselah T, Resche-Rigon M, Bedossa P, Valla D, et al.** Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. *Hepatology* 2006; 43: 1337-1345.
- **Sapienza MS, Porayko M.** Alpha-1 antitrypsin deficiency and liver disease. *Clinical Perspectives in Gastroenterology* 2002;5:40–8.
- **Schilsky, ML, Tavill, AS.** Schiff's Diseases of the Liver. Eugene R Schiff, Michael F. Sorrell, Willis C Maddrey, eds. 10[2], 1023. Lippincott, Williams & Wilkins, 2007.
- **Seeff LB.** Natural history of chronic hepatitis C. *Hepatology* 2002; 36:S35–46.
- **Sene D., Ghillani P., Thibault V., Guis L., Musset L., Duhaut P., Piette J., and Cacoub P.** Long Term Course of Mixed Cryoglobulinemia in Hepatitis C Virus-Infected patients. *J. Rheumatol.* 117-130., (3) 2004.
- **Sene D., Ghillani P., Thibault V.,** Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated

rheumatological manifestations and Sjögren's syndrome :Ann Rheum Dis 2006;65:394–397.

- **Sene D, Limal N, Cacoub P:** Hepatitis C virus-associated Extrahepatic manifestations; a review. Metabol Brain Dis 2004, 19:357–438.
- **Sergent JS, Lockshin MD, Christian CL, Gocke DJ.** Vasculitis with hepatitis B antigenemia: Long-term observation in nine patients. Medicine (Baltimore) 2005;55:1-18.
- **Shah VH.** Alcoholic Liver Disease : Mayo Clinic Gastroenterology and Hepatology Board Review **2008** chapter 24 :325-337.
- **Sharma NK, and Sherker AH,** 33-70 Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C : Clinical Gastroenterology: Chronic Viral Hepatitis, **2009**.
- **Sherlock S and Dooley J .** Alcohol and the Liver ; Diseases of the Liver and Biliary System: Chapter 22 ;2002: 381-395.

- **Sherlock S and Dooley J.** Chronic Hepatitis: General Features, and Autoimmune Chronic Disease: Diseases of the Liver and Biliary System **2002**: Chapter 19 ,321-335.
- **Shetty K , George YW:** Clinical gastroenterology ; Chronic Viral Hepatitis, 2009.
- **Siegal JL, Luthra H, Donlinger J, et al.** Association of Primary Biliary Cirrhosis and Rheumatoid Arthritis. Journal of clinical Rheumatology 2003;9(6):340-3.
- **Spangenberg HC, Thimme R, Blum HE.** Serum markers of hepatocellular carcinoma. Semin Liver Dis **2006**;26:385-390.
- **Sterling RK, Bralow Sp:** Extrahepatic Manifestations of Hepatitis C Virus: Current Gastroenterology Reports 2006, 8:53–59.
- **Sterling RK, Stravitz RT, Luketic VA, et al.** A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol **2004**;2(6):469.

- **Stoller JK, Aboussouan LS.** Alpha-1 antitrypsin deficiency. *Lancet* **2005**;365:2225–36.
- **Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C.** Delay in diagnosis of alpha-1 antitrypsin deficiency: a continuing problem. *Chest* **2005**;128:1989– 94.
- **Strassburg CP.** Autoimmune liver diseases: AIH, PBC and PSC *Hepatology A clinical textbook* **2009**, Chapter 27: 447-465 .
- **Strassburg Cp, Manns Mp (2004)** : [Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy]. *Internist (Berl)* 45:16-26.
- **Strassburg Cp, Manns Mp (2000)** Autoimmune tests in primary biliary cirrhosis. *Baillieres Best Pract Res Clin Gastroenterol* 14:585-599.
- **Svrtlih N, Jevtovic D, Simonovic J, et al.** Older age at the time of liver biopsy is the important risk factor for advanced

fibrosis in patients with chronic hepatitis C. *Hepatogastroenterology* **2007**;54(80):2324.

- **Talwalkar JA, Donlinger JJ, Gossard AA, Keach JC, Jorgensen RA, Petz JC, Lindor KD.** Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial. *Dig Dis Sci* 2006; 20: [Epub ahead of print].
- **Tarantino G , Riccio A , Span`o A , Loi G , Padula S , Ladogana P , etal.** HCV infection and chronic arthritis: Does viral replication matter? *Hepatology Research* 35 (2006) 238–241.
- **Targan SR, Landers G, Vidrich A,** High-Titer Antineutrophil Cytoplasmic Antibodies in Type-1 Autoimmune Hepatitis *Gastroenterology* 1995;108:1159-1166.
- **Telfer PT, Prestcott E, Holden S, et al.** Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. *Br J Haematol* 2000;110:971-977.

- **Timms AE, Sathananthan R, Bradbury L, et al.** Genetic testing for haemochromatosis in patients with chondrocalcinosis. *Ann Rheum Dis* 2002;61:745–7.
- **Travis S, Stevens R and Dalton H:** Shared Care in Gastroenterology Chapter 6 Abnormal liver function tests and chronic liver disease, **2005:** 66- 83.
- **Ulevitch RJ, Mathison JC, da Silva CJ.** Innate immune responses during infection. *Vaccine* 2004;22(Suppl 1):S25–30.
- **Vassilopoulos D, Calabrese LH.** Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. *Arthritis Res Ther* 2008; 10:215.
- **Vassilopoulos D, Manolakopoulos S:** Rheumatic manifestations of hepatitis :Current Opinion in Rheumatology 2009,21:1-6.
- **Vierling JM ;** The Immunology of Hepatitis B: *Clin Liver Dis* 11 (2007) 727–759.

-
- **Vigano M, Lampertico P, Rumi MG, Folli C, Maggioni L, et al.** Natural history and clinical impact of cryoglobulins in chronic Hepatitis C: 10-year prospective study of 343 patients. *Gastroenterology* 2007; 133: 835-42.
 - **Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, et al.** Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjogren's Syndrome. *Ann Rheum Dis* 1996;55:116–21.
 - **Vuppalanchi R, Liangpunsakul S, Chalasani N.** Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? *Am J Gastroenterol* 2007;102:558–62.
 - **Wasley A, Grytdal S, Gallagher K.** Surveillance for acute viral hepatitis--United States, 2006. *MMWR Surveill Summ* 2008;57(2):1.
 - **Wasmuth JC.** *Hepatology A clinical textbook*; Chapter 3: Hepatitis C - Epidemiology, transmission and natural history , 2009, 37-48.
-

- **Wasmuth JC:** hepatology 2009; Chapter 2: Hepatitis B - Epidemiology, transmission and natural history **25-37**.
- **Webster GJM, Hallett R, Whalley SA et al.** Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. *Lancet* 2000; **356**: 379.
- **Weismüller Tj, Wedemeyer J, Kubicka S et al. (2008):** The challenges in primary sclerosing cholangitis – Aetiopathogenesis, autoimmunity, management and malignancy. *J Hepatol* 48:S38-S57.
- **Whalley S ,Webster G, Barnes E and Dusheiko G** :chapter41;Viral Hepatitis Practical Gastroenterology **2004**.485-503.
- **Wieland SF, Chisari FV.** Stealth and cunning: hepatitis B and hepatitis C viruses. *J Virol* 2005;79(15):9369–80.
- **Wies I, Brunner S, Henninger J et al.** Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. *Lancet* **2000**; **355**: 1510.

- **Yokosuka O, Arai M.** Molecular biology of hepatitis B virus: Effect of nucleotide substitutions on the clinical features of chronic hepatitis B. *Med Mol Morphol* 2006; 39: 113–120.
- **Yuen MF, Lai CL.** Natural history of chronic hepatitis B virus infection. *J Gastroenterol Hepatol* 2000; 15(Suppl): E20–4.
- **Zhang P, Yu MY, Venable R, et al.** Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. *Proc Natl Acad Sci USA* 2006;103:9214–9.
- **Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB.** Extrahepatic manifestations of the Hepatitis C Virus infection: a general overview and guidelines for clinical approach. *Dig Liver Dis* 2007; 39: 2-17.
- **Zimmerman HJ.** Hepatotoxicity. The adverse effects of drugs and other chemicals in the liver, 2nd edn. Philadelphia: Lippincott Williams & Wilkins, 1999.

- **Zuckerman E, Keren D, Rozenbaum M, et al.** Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. *Clin Exp Rheumatol* 2000; 18:579—584.